Blood CB1, CB2, TRPV-1 concentration measurement: In each of the patients blood CB1, CB2, TRPV-1 concentration will be measure
Study summary
The main aim of the presented project will be to examine the concentration of selected receptors (CB1, CB2, TRPV-1) showing affinity for binding to cannabidol (CBD) and cannabinol (CBN) in blood samples collected from people with chronic pain in the masticatory muscles and from people without this pain. Moreover, study participants will be examined by a qualified doctor, according to the validated and standardized international DC/TMD protocol (Diagnostic Criteria for Temporomandibular Disorders) and the criteria included in ICOP-1 (International Classification of Orofacial Pain, 1st edition). The nature and duration of pain, psychoemotional state and central sensitization (the phenomenon of increased reactivity of the nervous system to stimuli) will be determined using validated questionnaires. The obtained results will be subjected to statistical analysis in order to check the relationships between the examined parameters.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* age over 18, under 80
* the presence of chronic pain in the muscles of the masticatory system, which lasts for more than 3 months in accordance with the international criteria included in ICOP-1.
Exclusion Criteria:
* people under 18 years of age
* pregnant or breastfeeding women,
* obese people,
* people with active cancer,
* people with severe systemic diseases, including genetic and neurological diseases,
* people with severe mental illnesses and taking psychoactive substances, people who are taking or have taken antidepressants and/or myorelaxants and/or other drugs that affect neuromuscular activity in the last 12 months
* people addicted to alcohol, drugs and other psychoactive substances
* condition after craniofacial injuries
Primary outcome measure(s)
Relationship between the concentration of receptors with affinity for Cannabidol and Cannabinol and the risk of occurrence and severity of chronic orofacial pain of muscle origin — May 5, 2024 - December 31, 2024 Each participant will undergo blood test focusing on CB1, CB2, TRPV-1 concentration
Assessment of the occurrence of chronic orofacial pain of muscular origin assessed using the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) protocol. — May 5, 2024 - December 31, 2024 Each patient will undergo DC/TMD protocol-based clinical examination using DC/TMD examination form assessing incidence of pain of masticatory muscles and surrounding structures.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
